Seagen

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Seagen reports robust Q4 earnings, poised for growth and innovation

Seagen's strong financial performance, focus on key products like ADCETRIS and PADCEV, and strategic investments in R&D position the company for continued growth.
While facing challenges in managing expenses and navigating competitive markets, Seagen's commitment to innovation and pipeline development presents opportunities for future success.
Overall, Seagen's performance in Q4 2022 reflects a company poised for growth, with a clear strategic focus on optimizing its commercial portfolio and advancing clinical programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.  The company was founded in 1997 and is headquartered in Bothell, Washington.

BOTHELL, Wash.--( BUSINESS WIRE )--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.

Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023

AbbVie

Abbott Labs

Alnylam Pharmaceuticals

Amgen

argenx

AstraZeneca

Baxter

Bayer AG

BeiGene

Biogen

Bristol-Myers

United States Brent Oil Fund LP

BioNTech SE

CSL Ltd

Invesco DB Oil Fund

Daiichi Sankyo Co Ltd

Gilead Sciences

Genmab - ADR

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

Incyte

Johnson & Johnson

Eli Lilly

Merck

Moderna

Novo Nordisk

Novartis

VanEck Vectors Oil Services ETF

iPath Pure Beta Crude Oil ETN

Pfizer

Invesco Dynamic Oil & Gas Services ETF

Reckitt Benckiser Group PLC

Regeneron Pharmaceuticals

Roche Holding AG

Royalty Pharma

Takeda Pharmaceutical

ProShares Ultra Bloomberg Crude Oil

United States Oil Fund LP

Vertex Pharmaceuticals

SPDR S&P Oil & Gas Exploration & Production ETF

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Oil Stocks And Medicals Shine

SGEN has been under pressure since a rumored takeover deal by pharmaceutical giant Merck & Co. fell through last summer. The company last reported its Q3 earnings with stronger than expected sales, with an expectation of further topline momentum into 2023.

Seagen: 2023 Shaping Up To Be A Breakout Year

BOTHELL, Wash.--( BUSINESS WIRE )--Seagen Inc. (Nasdaq:SGEN) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:00 p.m. Pacific Time. The presentation will be webcast live and available for replay from the investor section of Seagen's website at investor.seagen.com.

Seagen to Present at the J.P. Morgan Healthcare Conference

– This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting – – FDA granted the applications Priority Review with a PDUFA date of April 21, 2023 – TOKYO, BOTHELL, Wash. and RAHWAY, N.J.

Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Uro

BOTHELL, Wash. & TOKYO & RAHWAY, N.J.--( BUSINESS WIRE )--Seagen Inc. (Nasdaq: SGEN), Astellas Pharma Inc. (TSE:4503) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review supplemental Biologics License Applications (sBLAs) for PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) for use of these two agents in combination for the treatment of patients with locally advanced or metastatic urothelial cancer (la/mUC) who are not eligible to receive cisplatin-containing chemotherapy. The respective applications are intended to expand both labels for PADCEV and KEYTRUDA. The agency set a Prescription Drug User Fee Act (PDUFA) goal date for each application of April 21, 2023.

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Seagen Inc SGEN shares are trading higher by 4.79% to $129.94 by after the company announced results from the Phase 2 clinical trial of ADCETRIS with novel immunotherapy combination in patients with advanced- and early-stage classical Hodgkin Lymphoma.

Why Seagen Stock Is Trading Higher During Monday's Session - Seagen (NASDAQ:SGEN)

BOTHELL, Wash.--( BUSINESS WIRE )--Seagen Inc. (Nasdaq: SGEN) today announced results from two parts of a phase 2 trial (SGN35-027) evaluating ADCETRIS® (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) for the frontline treatment of patients with classical Hodgkin lymphoma (cHL). Part B of the trial evaluated patients with advanced-stage disease and was presented as an oral presentation, and Part C evaluated patients with early-stage disease and was presented as a poster at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

Celsius Holdings

Copa Hlds

Equinor

Horizon Pharma

Lattice Semiconductor

Monster Beverage

PepsiCo

An array of top stocks in a wide variety of industries are building cup bases as the stock market recovers. The post Top Stocks In Multiple Industries Build Bases As Market Gains Strength appeared first on Investor's Business Daily.

Top Stocks In Multiple Industries Build Bases As Market Gains Strength

Alphabet

These stocks aren't bargain buys just yet, but they could be soon.

2 Growth Stocks to Buy if the Bear Market Continues in 2023

BOTHELL, Wash.--( BUSINESS WIRE )--Seagen Inc. (Nasdaq: SGEN) today announced new data for ADCETRIS® (brentuximab vedotin) will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 10-13, 2022. The abstracts, including five oral presentations, highlight updated and interim efficacy and safety clinical trial results for ADCETRIS in both early- and advanced stage settings of classical Hodgkin lymphoma (cHL), and in patients with other CD30-expressing lymphomas and other rare cancers.

Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting

Bio-Rad Laboratories

Catalent

DexCom

Edwards Lifesciences

Intuitive Surgical

West Pharmaceutical Services

The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.

These Are the Five Best and Worst Performing Healthcare Stocks in October 2022

The FDA approves Seagen's (SGEN) Adcetris for a new indication, treating pediatric patients with previously untreated high-risk Hodgkin lymphoma. The company also appoints a new CEO.

Seagen (SGEN) Adcetris Label Expansion OK'd, New CEO Named

Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

Biogen and Seagen tapped new CEOs on Thursday but the biotech stocks diverged following the long-anticipated announcements. The post Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles appeared first on Investor's Business Daily.

Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles

Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting

Seagen Appoints Sandra M. Swain, M.D.

Seagen Names David R. Epstein as Chief Executive Officer and Director

Seagen (SGEN) reports a wider-than-expected loss in the third quarter of 2022 while its revenues beat estimates. The company raises total revenue guidance for 2022.

Seagen's (SGEN) Q3 Earnings Miss, Revenues Surpass Estimates

Seagen Inc. (NASDAQ:SGEN ) Q3 2022 Earnings Conference Call October 27, 2022 4:30 PM ET Company Participants Doug Maffei - Vice President, Investor Relations Roger Dansey - Interim Chief Executive Officer and Chief Medical Officer Todd Simpson - Chief Financial Officer Chip Romp - Executive Vice President, Commercial U.S. Conference Call Participants Michael Schmidt - Guggenheim Andrew Berens - SVB Securities Jeff Hung - Morgan Stanley Jay Olson - Oppenheimer Gregory Renza - RBC Capital Markets Andy Hsieh - William Blair Operator Good day and welcome to the Seagen Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please note, today's event is being recorded.

Seagen Inc. (SGEN) Q3 2022 Earnings Call Transcript

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -11.96% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates

Seagen Reports Third Quarter 2022 Financial Results

It's growing faster than competitors, but headwinds might soon bog it down.

Is Seagen Stock a Buy Now?

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Conference call and webcast information: Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 1

Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022

As it successfully transitioned into a commercial-stage operator, Seagen is enjoying great progress. The four drugs powering Seagen's marketed portfolio are generating robust revenue growth.

Seagen: A Stellar Portfolio Anchor

News for Seagen Stock (SGEN)